100 Migraine Drugs, A to Z: pregabalin

June 19, 2020

Pregabalin (Lyrica) is an epilepsy drug that is also approved by the FDA for the treatment of neuropathic (nerve) pain associated with diabetes, spinal cord injury, shingles (herpes zoster), and fibromyalgia. It is a controlled drug with a low risk of addiction and abuse, although it is often combined with other illicit drugs. Common side effects include dizziness, drowsiness, difficulty thinking clearly, weight gain, sexual dysfunction, and dry mouth. It also has many other less common side effects.

There are no large controlled trials of pregabalin for migraines only case series and anecdotal reports. However, because it does relieve pain and because two other epilepsy drugs, topiramate (Topamax, Trokendi, Qudexi) and divalproex sodium (Depakote) relieve migraines, at least theoretically it should be also effective for migraines. However, despite the few anecdotal reports, it does not appear to be very effective and often does cause side effects. I rarely prescribe it and have very few patients who benefit from it without side effects.

Written by
Alexander Mauskop, MD
Continue reading
September 7, 2025
How Artificial Sweeteners May Be Affecting Your Brain
A large Brazilian study published in Neurology followed nearly 13,000 adults for eight years and found something troubling: people who consumed the most artificial sweeteners showed faster cognitive...
Read article
August 30, 2025
Lithium Levels are low in Alzheimer’s. Is there a role in Migraine and Chronic Pain?
Recently published research on lithium deficiency in Alzheimer’s disease has caught the attention of the media. As a neurologist specializing in pain and headache medicine with an interest in no...
Read article
August 16, 2025
The Healing Power of Holding Hands: Insights from Neuroscience on Pain Relief
There’s something powerful about human touch when you’re hurting. As a neurologist, I see every day how a gentle hand squeeze from someone you trust can shift your pain—not just emotionally, but in...
Read article